Medusa Pharmaceuticals: Revision history

3 September 2022

• curprev 16:2716:27, 3 September 2022‎ Manos talk contribs‎ 5,809 bytes +57‎ No edit summary undo Tag: Visual edit: Switched

14 August 2022

• curprev 11:3911:39, 14 August 2022‎ 103.126.60.198 talk‎ 5,752 bytes +26‎ No edit summary undo Tag: Visual edit: Switched

13 August 2022

• curprev 23:3923:39, 13 August 2022‎ 109.180.50.163 talk‎ 5,726 bytes −10‎ No edit summary undo Tag: Visual edit
• curprev 23:3923:39, 13 August 2022‎ 109.180.50.163 talk‎ 5,736 bytes +61‎ Undo revision 27848 by 109.180.50.163 (talk) undo Tag: Undo
• curprev 12:2712:27, 13 August 2022‎ 109.180.50.163 talk‎ 5,675 bytes −61‎ No edit summary undo Tag: Visual edit: Switched

22 July 2022

• curprev 17:5917:59, 22 July 2022‎ Louis talk contribs‎ 5,736 bytes +42‎ No edit summary undo Tag: Visual edit

2 March 2022

• curprev 22:3022:30, 2 March 2022‎ Rachel talk contribs‎ 5,694 bytes +5,694‎ Created page with "Reinvigorating antibiotics by repurposing approved drugs to overcome AMR '''About Medusa Pharmaceuticals:''' Medusa Pharmaceuticals is an Imperial College London spin-out based on a serendipitous discovery: synergy between an aminoglycoside antibiotic and an alkylating agent, able to overcome antimicrobial resistance, treating lethal infections. We are developing a discovery platform to generate a powerful suite of broadly targeting combination therapeutics optimised..."